...
首页> 外文期刊>Canadian journal of gastroenterology >Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic.
【24h】

Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic.

机译:加拿大艾滋病毒-丙型肝炎病毒合并感染三级护理诊所中丙型肝炎病毒治疗的障碍。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Despite demonstrated efficacy in HIV-hepatitis C virus (HCV) coinfection, not all patients initiate, complete or achieve success with HCV antiviral therapy. PATIENTS AND METHODS: All HIV-HCV coinfected patient consults received at The Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Ontario) between June 2000 and September 2006 were identified using a clinical database. A descriptive analysis of primary and contributing factors accounting for why patients did not initiate HCV therapy, as well as the therapeutic outcomes of treated patients, was conducted. RESULTS: One hundred two consults were received. Sixty-seven per cent of patients did not initiate HCV therapy. The key primary reasons included: HIV therapy was more urgently needed (22%), loss to follow-up (12%), patients were deemed unlikely to progress to advanced liver disease (18%) and patient refusal (12%). Many patients had secondary factors contributing to the decision not to treat, including substance abuse (23%) and psychiatric illness (14%). Overall, 59% of untreated patients (40 of 68) were eventually lost to follow-up. Thirty-three per cent of referred patients started HCV therapy. Twenty-seven of 42 courses (64%) were interrupted prematurely for reasons such as virological nonresponse (48%), psychiatric complications (10%) and physical side effects (7%). Of all treatment recipients, 12 of 42 full courses of therapy were completed and three remained on HCV medication. Overall, eight of the 102 coinfected patients studied (8%) achieved a sustained virological response. DISCUSSION: Not all HIV-HCV coinfected patients who are deemed to be in need of HCV treatment are initiating therapy. Only a minority of patients who do receive treatment achieve success. Implementation of HIV treatment, patient retention, attention to substance abuse and mental health care should be the focus of efforts designed to increase HCV treatment uptake and success. This can be best achieved within a multidisciplinary model of health care delivery.
机译:背景:尽管已证明可在HIV-丙型肝炎病毒(HCV)合并感染中发挥功效,但并非所有患者都可以通过HCV抗病毒治疗来开始,完成或取得成功。患者和方法:使用临床数据库确定了2000年6月至2006年9月间在渥太华医院病毒性肝炎诊所(安大略省渥太华)接受的所有HIV-HCV合并感染的患者咨询。进行了描述性分析,解释了为什么患者不开始HCV治疗的主要和贡献因素,以及所治疗患者的治疗结果。结果:收到了102次咨询。 67%的患者未开始HCV治疗。关键的主要原因包括:迫切需要HIV治疗(22%),失去随访(12%),被认为不太可能进展为晚期肝病(18%)和拒绝患者(12%)。许多患者的次要因素(包括药物滥用(23%)和精神病(14%))有助于决定不治疗。总体而言,未治疗的患者中有59%(68名患者中的40名)最终失去了随访。 33%的转诊患者开始进行HCV治疗。 42个疗程中有27个疗程(64%)因病毒学无应答(48%),精神病并发症(10%)和身体副作用(7%)等原因而提前中断。在所有接受治疗的人中,完成了42个完整疗程的12个疗程,其中3个仍使用HCV药物治疗。总体而言,在研究的102位合并感染患者中,有8位(8%)实现了持续的病毒学应答。讨论:并非所有被认为需要HCV治疗的合并HIV-HCV的患者都开始治疗。只有少数接受治疗的患者才能获得成功。实施HIV治疗,保留患者,注意药物滥用和精神保健应成为旨在增加HCV治疗吸收率和成功率的工作重点。这可以在卫生保健的多学科模型中最好地实现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号